Charles Schwab Investment Management Inc Biocryst Pharmaceuticals Inc Transaction History

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,979,992 shares of BCRX stock, worth $17.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,979,992

Previous 1,887,994 4.87%

Holding current value

$17.5 Million

Previous $14.3 Million 3.77%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$7.03 - $8.43 $646,745 - $775,543	91,998 Added 4.87%	1,979,992 $14.9 Million
Q3 2024 Nov 12, 2024	BUY	$6.41 - $8.69 $659,332 - $893,853	102,860 Added 5.76%	1,887,994 $14.3 Million
Q2 2024 Aug 12, 2024	BUY	$4.13 - $6.79 $220,257 - $362,117	53,331 Added 3.08%	1,785,134 $11 Million
Q1 2024 May 08, 2024	BUY	$4.89 - $7.65 $671,724 - $1.05 Million	137,367 Added 8.62%	1,731,803 $8.8 Million
Q4 2023 Feb 06, 2024	BUY	$4.98 - $6.77 $665,472 - $904,668	133,629 Added 9.15%	1,594,436 $9.55 Million
Q3 2023 Nov 08, 2023	BUY	$6.71 - $7.92 $130,187 - $153,663	19,402 Added 1.35%	1,460,807 $10.3 Million
Q2 2023 Aug 09, 2023	BUY	$6.96 - $8.81 $127,263 - $161,090	18,285 Added 1.28%	1,441,405 $10.1 Million
Q1 2023 May 11, 2023	BUY	$7.94 - $11.84 $21,700 - $32,358	2,733 Added 0.19%	1,423,120 $11.9 Million
Q4 2022 Feb 13, 2023	BUY	$10.5 - $14.2 $359,509 - $486,193	34,239 Added 2.47%	1,420,387 $16.3 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $314,474 - $431,637	29,145 Added 2.15%	1,386,148 $17.5 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $80,178 - $181,696	10,162 Added 0.75%	1,357,003 $14.4 Million
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $832,620 - $1.42 Million	72,026 Added 5.65%	1,346,841 $21.9 Million
Q4 2021 Feb 11, 2022	BUY	$11.18 - $15.46 $342,655 - $473,833	30,649 Added 2.46%	1,274,815 $17.7 Million
Q3 2021 Nov 16, 2021	BUY	$14.21 - $17.65 $242,351 - $301,020	17,055 Added 1.39%	1,244,166 $17.9 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $191,377 - $347,299	20,145 Added 1.67%	1,227,111 $19.4 Million
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $282,086 - $520,922	38,275 Added 3.28%	1,206,966 $12.3 Million
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $4,566 - $11,666	-1,355 Reduced 0.12%	1,168,691 $8.71 Million
Q3 2020 Nov 13, 2020	BUY	$3.43 - $5.53 $830,409 - $1.34 Million	242,102 Added 26.09%	1,170,046 $4.02 Million
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $130,980 - $386,736	68,937 Added 8.03%	927,944 $4.42 Million
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $38,012 - $97,645	23,758 Added 2.84%	859,007 $1.72 Million
Q4 2019 Feb 07, 2020	BUY	$1.59 - $3.45 $412,514 - $895,078	259,443 Added 45.06%	835,249 $2.88 Million
Q3 2019 Nov 08, 2019	SELL	$2.5 - $3.73 $192,317 - $286,937	-76,927 Reduced 11.79%	575,806 $1.65 Million
Q2 2019 Aug 09, 2019	SELL	$2.91 - $9.15 $368,499 - $1.16 Million	-126,632 Reduced 16.25%	652,733 $2.47 Million
Q1 2019 May 14, 2019	BUY	$7.38 - $9.72 $1.34 Million - $1.76 Million	181,543 Added 30.37%	779,365 $6.35 Million
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $117,707 - $173,577	-18,081 Reduced 2.94%	597,822 $4.83 Million
Q3 2018 Nov 13, 2018	BUY	$5.52 - $7.99 $534,573 - $773,775	96,843 Added 18.66%	615,903 $4.7 Million
Q2 2018 Aug 08, 2018	BUY	$4.6 - $6.52 $129,186 - $183,107	28,084 Added 5.72%	519,060 $2.98 Million
Q1 2018 May 07, 2018	SELL	$4.35 - $5.82 $25,299 - $33,849	-5,816 Reduced 1.17%	490,976 $2.34 Million
Q4 2017 Jan 17, 2018	BUY	$4.16 - $5.33 $735,130 - $941,885	176,714 Added 55.21%	496,792 $2.44 Million
Q3 2017 Nov 13, 2017	BUY	$4.1 - $5.97 $1.31 Million - $1.91 Million	320,078	320,078 $1.68 Million

Others Institutions Holding BCRX

# of Institutions

277

Shares Held

172M

Call Options Held

610K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.64B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Biocryst Pharmaceuticals Inc Transaction History